Physician profile
Hadiza E Hamza
NPI 1609891514
$820.28
in general payments reported to CMS, 2019-2025
11 companies · $140 in 2025
The $140 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $147 · 2023: $53.37 · 2024: $481 · 2025: $140.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $674.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $673.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intra-Sana Laboratories | $369.07 | 2024 | Glycate, Reltone 200 Mg, Reltone 400 Mg |
| Novo Nordisk INC | $104.13 | 2022-2024 | Wegovy, Rybelsus |
| Amgen INC. | $86.34 | 2024-2025 | Repatha, Otezla, Repatha |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $54.20 | 2022-2024 | Caplyta |
| Myriad Genetic Laboratories, INC. | $50.00 | 2025 | Prolaris |
| Lucid Diagnostics INC. | $36.30 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $35.82 | 2025 | |
| Alkermes, INC. | $30.39 | 2022-2024 | Aristada, Lybalvi |
| Impel Pharmaceuticals INC. | $22.14 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.81 | 2025 | Xifaxan |
| Glaxosmithkline, LLC. | $14.08 | 2023 | Arexvy, Shingrix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hadiza Hamza listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.